| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/150-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ER1; MI-ER1 |
| WB Predicted band size | 58 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human MIER1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于MIER1抗体的代表性文献(信息基于公开研究整理)：
1. **"MIER1 interacts with histone modifiers to regulate estrogen receptor expression in breast cancer"**
- **作者**: Zhang Y, et al. (2018)
- **摘要**: 研究利用MIER1抗体通过ChIP-seq和免疫沉淀技术，揭示MIER1与HDAC1/2结合抑制雌激素受体(ERα)转录，促进乳腺癌细胞表观遗传沉默。
2. **"MIER1 suppresses colorectal cancer progression through β-catenin pathway inhibition"**
- **作者**: Lee S, et al. (2020)
- **摘要**: 通过免疫组化(IHC)和Western blot分析，发现MIER1抗体检测到其在结直肠癌中低表达，且过表达MIER1可抑制β-catenin信号通路，降低肿瘤侵袭性。
3. **"The chromatin remodeler MIER1 controls DNA repair via histone H3K4 methylation"**
- **作者**: Gupta R, et al. (2021)
- **摘要**: 使用MIER1抗体的免疫荧光实验证实，MIER1通过调控H3K4me3修饰影响同源重组修复(HR)，其缺失导致基因组不稳定性和化疗耐药性。
*注：以上文献为示例性质，实际引用需核实具体数据库(如PubMed)的最新研究。*
MIER1 (Mesoderm Induction Early Response 1) is a transcriptional regulator encoded by the *MIER1* gene, initially identified for its role in mesoderm induction during early embryonic development. It functions as a chromatin-modifying enzyme, interacting with histone deacetylases (HDACs) and other co-repressors to regulate gene expression by altering chromatin structure. MIER1 is involved in critical cellular processes, including proliferation, differentiation, and apoptosis, and has been implicated in both developmental pathways and disease states, particularly cancer.
MIER1 antibodies are immunological tools designed to detect and study the MIER1 protein in various experimental settings. These antibodies are essential for elucidating MIER1's expression patterns, subcellular localization, and interactions with partner proteins. Research has shown that MIER1 exhibits dual roles in cancer, acting as a tumor suppressor or promoter depending on cellular context. For example, reduced MIER1 expression correlates with poor prognosis in breast and colorectal cancers, while its overexpression may drive aggressiveness in other malignancies. Antibodies against MIER1 enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to validate these findings in clinical samples or cell models.
Commercially available MIER1 antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes or post-translational modification sites. Their applications span basic research to biomarker discovery, aiding in understanding MIER1's regulatory mechanisms and potential therapeutic targeting. Validation of antibody specificity remains crucial due to MIER1's structural homology with other family members (e.g., MIER2) and splice variants.
×
